L Raz1, L V Hunter1, N M Dowling2,3, W Wharton4, C E Gleason3, M Jayachandran1, L Anderson1, S Asthana3, V M Miller1,5. 1. a Department of Physiology and Biomedical Engineering , Mayo Clinic , Rochester , Minnesota , USA ; 2. b Department of Biostatistics and Medical Informatics , University of Wisconsin , Madison , WI , USA ; 3. c Department of Medicine , University of Wisconsin and Geriatric Research, Education and Clinical Center, Madison VA Hospital , Madison , WI , USA ; 4. d Department of Neurology , Emory University , Atlanta , GA , USA ; 5. e Department of Surgery , Mayo Clinic , Rochester , Minnesota , USA.
Abstract
BACKGROUND:Serotonin (5-hydroxytryptamine, 5-HT) is modulated by sex steroid hormones and affects vascular function and mood. In the Kronos Early Estrogen Prevention Cognitive and Affective Ancillary Study (KEEPS-Cog), women randomized to oral conjugated equine estrogens (oCEE) showed greater benefit on affective mood states than women randomized to transdermal 17β-estradiol (tE2) or placebo (PL). This study examined the effect of these treatments on the platelet content of 5-HT as a surrogate measure of 5-HT synthesis and uptake in the brain. METHODS: The following were measured in a subset (n = 79) of women enrolled in KEEPS-Cog: 5-HT by ELISA, carotid intima-medial thickness (CIMT) by ultrasound, endothelial function by reactive hyperemic index (RHI), and self-reported symptoms of affective mood states by the Profile of Mood States (POMS) questionnaire. RESULTS:Mean platelet content of 5-HT increased by 107.0%, 84.5% and 39.8%, in tE2, oCEE and PL groups, respectively. Platelet 5-HT positively correlated with estrone in the oCEE group and with 17β- estradiol in the tE2 group. Platelet 5-HT showed a positive association with RHI, but not CIMT, in the PL and oCEE groups. Reduction in mood scores for depression-dejection and anger-hostility was associated with elevations in platelet 5-HT only in the oCEE group (r = -0.5, p = 0.02). CONCLUSIONS: Effects of oCEE compared to tE2 on RHI and mood may be related to mechanisms involving platelet, and perhaps neuronal, uptake and release of 5-HT and reflect conversion of estrone to bioavailable 17β-estradiol in platelets and the brain.
RCT Entities:
BACKGROUND:Serotonin (5-hydroxytryptamine, 5-HT) is modulated by sex steroid hormones and affects vascular function and mood. In the Kronos Early Estrogen Prevention Cognitive and Affective Ancillary Study (KEEPS-Cog), women randomized to oral conjugated equine estrogens (oCEE) showed greater benefit on affective mood states than women randomized to transdermal 17β-estradiol (tE2) or placebo (PL). This study examined the effect of these treatments on the platelet content of 5-HT as a surrogate measure of 5-HT synthesis and uptake in the brain. METHODS: The following were measured in a subset (n = 79) of women enrolled in KEEPS-Cog: 5-HT by ELISA, carotid intima-medial thickness (CIMT) by ultrasound, endothelial function by reactive hyperemic index (RHI), and self-reported symptoms of affective mood states by the Profile of Mood States (POMS) questionnaire. RESULTS: Mean platelet content of 5-HT increased by 107.0%, 84.5% and 39.8%, in tE2, oCEE and PL groups, respectively. Platelet 5-HT positively correlated with estrone in the oCEE group and with 17β- estradiol in the tE2 group. Platelet 5-HT showed a positive association with RHI, but not CIMT, in the PL and oCEE groups. Reduction in mood scores for depression-dejection and anger-hostility was associated with elevations in platelet 5-HT only in the oCEE group (r = -0.5, p = 0.02). CONCLUSIONS: Effects of oCEE compared to tE2 on RHI and mood may be related to mechanisms involving platelet, and perhaps neuronal, uptake and release of 5-HT and reflect conversion of estrone to bioavailable 17β-estradiol in platelets and the brain.
Authors: S Mitchell Harman; Dennis M Black; Frederick Naftolin; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Paul N Hopkins; Rogerio A Lobo; JoAnn E Manson; George R Merriam; Virginia M Miller; Genevieve Neal-Perry; Nanette Santoro; Hugh S Taylor; Eric Vittinghoff; Mingzhu Yan; Howard N Hodis Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: P Guicheney; D Léger; J Barrat; R Trévoux; B De Lignières; P Roques; J P Garnier; P Boyer; J Grenier; C Dreux Journal: Eur J Clin Invest Date: 1988-06 Impact factor: 4.686
Authors: Dahima Cintron; John P Beckman; Kent R Bailey; Brian D Lahr; Muthuvel Jayachandran; Virginia M Miller Journal: Maturitas Date: 2017-02-17 Impact factor: 4.342
Authors: Virginia M Miller; Fredrick Naftolin; Sanjay Asthana; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Carey E Gleason; Howard N Hodis; Muthuvel Jayachandran; Kejal Kantarci; Rogerio A Lobo; JoAnn E Manson; Lubna Pal; Nanette F Santoro; Hugh S Taylor; S Mitchell Harman Journal: Menopause Date: 2019-09 Impact factor: 2.953
Authors: V M Miller; H S Taylor; F Naftolin; J E Manson; C E Gleason; E A Brinton; J M Kling; M I Cedars; N M Dowling; K Kantarci; S M Harman Journal: Climacteric Date: 2020-09-03 Impact factor: 3.005
Authors: Laura Faubion; Thomas A White; Brett J Peterson; Jennifer R Geske; Nathan K LeBrasseur; Marissa J Schafer; Michelle M Mielke; Virginia M Miller Journal: Physiol Rep Date: 2020-08